TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04564495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated exercise
Description: Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Seated exercise
Description: Exercise will include repetitive bouts of high intensity exercises with intermittent periods of rest or active recovery. circuit of moves like 'jabs', 'hooks' etc, and a strength and endurance class that promotes postural awareness.
Study: NCT05616026

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: 6 months of texts for general health promotion
Study: NCT06500975

Intervention type: DEVICE
Intervention: Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Description: Continuously motion-modulated stimulation delivered by a vestibular implant already implanted under a prior study protocol (Labyrinth Devices MVI™ Multichannel Vestibular Implant System)
Study: NCT05458011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study: NCT05458011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study: NCT05255653

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).
Study: NCT06237257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316（Adebrelimab Injection）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection/Carboplatin Injection
Description: Cisplatin Injection/Carboplatin Injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)/Brachytherapy
Description: External Beam Radiotherapy (EBRT)/Brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Injection
Description: Paclitaxel Injection.
Study: NCT05869851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pavlik Harness
Description: The Pavlik harness is an abduction brace used for treatment of hip dysplasia in infants. It keeps the hips in proper alignment to allow for appropriate growth and development of the joint.
Study: NCT05255653

Intervention type: RADIATION
Group type: OTHER
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy
Description: Vaginal brachytherapy is to be considered in patients with documented cervical stromal involvement and/or substantial LVSI. Brachytherapy is given with a vaginal cylinder or vaginal ovoids or ring applicator, according to the center's standard technique. When using a cylinder, the active length will ideally be 2-3 cm, with the reference isodose covering the proximal 2.5-3 cm of the vagina. High-dose-rate (HDR) and pulse-dose-rate (PDR) schedules are permitted, which deliver an EQD2 equivalent dose of 10-14 Gy at 5 mm from the vaginal mucosa (to obtain a cumulative EDQ2 of 60 Gy at 5 mm).

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: No adjuvant therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: No adjuvant therapy
Study: NCT05119985

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral vein cannulation
Description: The target vein is directly identified by ultrasound, the procedure of peripheral venous catheter insertion is performed conventionally, without ultrasound guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulation without ultrasound
Description: Cannulation is done the conventional way without any ultrasound use.
Study: NCT06419231

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate Formulation
Description: Butyrate Formulation capsule: Take daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butyrate + Polyphenol Formulation
Description: Butyrate + Polyphenol Formulation capsule: Take daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Take daily
Study: NCT06206213

Intervention type: BEHAVIORAL
Intervention: Assessment of two different locomotion types.
Description: Exposure to virtual environment by the HMD in two different locomotion styles.
Study: NCT06525311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-808
Description: K-808 single or multi dose extended-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-808
Description: K-808 single or multi dose extended-release tablets
Study: NCT05350592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Single bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Single bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Continous weight-adjusted infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Continous weight-adjusted infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: Placebo comparator and diluent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Placebo comparator and diluent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9%
Description: Placebo comparator and diluent
Study: NCT06134167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Compress Device
Description: Study participants will undergo surgical implantation of the Transdermal Compress device on Study Day 1. Participants will be followed through the end of the study as they complete rehabilitation.
Study: NCT05007717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data-informed Stepped Care (DiSC)
Description: The DiSC intervention is comprised of a data-driven system to assign adolescents to care based on their health needs and the different levels of care for each assignment group.~The trajectory of services moves from a relative position of ALHIV autonomy to more intensive service provision. Intervention steps start with 1) multi-month refills or community treatment delivery (differentiated care); 2) a standard of care level for those with medical needs such as pregnancy or opportunistic infections or patient choice; 3) patient reminders/tracking and counseling and referral services for mental health needs; 4) case management of unsuppressed individuals, including enhanced counseling and case conference problem-solving
Study: NCT04931212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FETO with Smart-TO balloon
Description: Fetal endoscopic tracheal occlusion using the Smart-TO balloon Unplug procedure by peripheral course around the MR scanner
Study: NCT05005442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/vibostolimab coformuation
Description: Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.
Study: NCT06581146

Intervention type: OTHER
Intervention: No Intervention
Description: No investigational drug will be administered to participants in this study.
Study: NCT04953052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: An isotonic sterile solution of imatinib.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An isotonic sterile solution
Study: NCT05088863

Intervention type: OTHER
Group type: OTHER
Intervention: flaxseed
Description: 40g of flaxseed per day
Study: NCT06143423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP026 (TQA2226) for injection
Description: AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP026 (TQA2226) for injection
Description: AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.
Study: NCT06191978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study: NCT06695858

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ESPB
Description: Patients received bilateral ultrasound-guided ESPB using 20 mL bupivacaine 0.25% on each side.
Study: NCT06686875

Intervention type: OTHER
Intervention: Questionnaire
Description: Patients will receive a link to a web-based questionnaire on the prevalence and characteristics of pain symptoms including the PainDETECT questionnaire.
Study: NCT06460467

Intervention type: DEVICE
Intervention: scintigraphy of 177Lu-DOTATATE
Description: The medical device under study is a hybrid wide-field CZT solid-state camera, the VERITON-CT ™ camera.
Study: NCT06696430

Intervention type: BEHAVIORAL
Intervention: Educational Intervention on TENS Usage
Description: Educational sessions on TENS usage and support from designated superusers to increase knowledge and skills related to TENS for postoperative pain management.

Intervention type: BEHAVIORAL
Intervention: Nudging Intervention to Promote TENS Usage
Description: Healthcare staff exposed to nudging strategies designed to enhance the use of TENS, which involves visual prompts, reminders, and environmental cues aimed at making TENS more salient and encouraging its use for postoperative pain management.
Study: NCT06698094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainable lifestyle
Description: To encourage and nudge a sustainable lifestyle in an office context in order to improve public health and combat climate change.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle
Description: To encourage and nudge a healthy lifestyle in an office context, the participants in this arm will function as a control group receiving general recommendations based on NNR 2014 nutritional recommendations and WHO physical activity recommendations.
Study: NCT06697262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote temperature monitoring device
Description: * Use of the Tucky® remote monitoring device for continuous temperature monitoring at home,~* In combination with education sessions on temperature monitoring and the device.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Home temperature monitoring by a nurse
Description: * Home temperature monitoring by a nyrse, twice a day,~* In association with education sessions on temperature monitoring.
Study: NCT06697366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection Ⅱ
Description: 56.6 mg/m2，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg，Q3W
Study: NCT04302493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: Participants randomized to the MBSR arm will undergo a standard 8 week course of MBSR taught by a psychologist trained in the MBSR protocol and encouraged to engage in additional individual mindfulness sessions using a cell phone application.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Support Group (SSG)
Description: As a control group, participants randomized to the SSG arm will participate in 8 weeks of weekly Stroke Support Group sessions to experience activity and socialization without additional mindfulness training.
Study: NCT05657054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention Targeting Hip Strengthening
Description: An initial 16-week exercise intervention of 45 minutes of training 3 times a week in the patient's own home or at a rehabilitation center. Patients will be instructed by a physiotherapist during the first 3 sessions, in order to be able to perform the exercises at home. Subsequently, there are physiotherapist-supervised sessions once every second week. The delivery of the supervised sessions is based on the patient's preferences, either by physical attendance or remotely in the patient's home. The intervention will consist of 4 exercises adapted from the NEMEX program targeting lower extremity muscle strength, stability, postural function, and postural orientation. Progression is made when an exercise is performed with good sensorimotor control and good performance quality and with minimal exertion and adequate movement control. Progression is primarily provided by 3 levels of difficulty and secondly by varying the number of repetitions or where possible, by increasing the weight load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The intervention will consist of a rehabilitation intervention corresponding to standard care in the participating municipalities (i.e. content and duration of intervention). The intervention will be delivered individually or as group training, based on a clinical assessment of the individual patients' needs. The intervention can be supported by home-based exercises following instruction from a physiotherapist, supplemented by the provision of written information or access to a virtual training program. The intervention occurs in either the rehabilitation center's gym or the patient's home. The training sessions may consist of some of the following parameters: Strength training, stretching, functional training e.g. walking and stair climbing, stability training, balance training, endurance training, and gait correction.
Study: NCT05942027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo match Coenzyme Q10 capsules once per day .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-Enzyme Q10
Description: Patients will be treated with Coenzyme Q10 capsules (CoQ10) 200 mg/day.
Study: NCT06474663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV
Study: NCT06080048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR102
Description: SOR102 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOR102
Description: SOR102 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT06544057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-MI
Description: CBT-MI combines elements from Cognitive Behavioural Therapy and Motivational Interviewing in treating nicotine addiction, delivered remotely via Zoom by trained 'layperson coaches'
Study: NCT06245629

Intervention type: DRUG
Intervention: Bortezomib-bendamustine-melphalan
Description: The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.
Study: NCT06697522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate
Description: low concentration atropine (0.01%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank comparator
Study: NCT06696651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical myostimulation
Description: Electrical myostimulation in form of suit as in fig. Blue lines demonstrate areas of electrodes inside suit. twenty females will receive EMS session per week ( 20mins / week ) and following healthy diet for 6 weeks . 20 min = 1 min warm up, 6min upper body training, 6min lower body training, 6min core training, 1 min cooling down.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electronic cupping
Description: Twenty females will undergo two weekly myofascial release sessions and a healthy diet for six weeks, using electronic cupping to ensure equal pressure on tender points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Description: The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet
Description: The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: healthy diet
Description: The MedDiet diet focuses on high fat intake, primarily from extra-virgin olive oil, in vegetable dishes, and a high consumption of low-glycemic index carbohydrates like wholegrain cereals, legumes, nuts, fruits, and vegetables. Moderate to high fish consumption is also encouraged, with moderate to small amounts of poultry and dairy products. Red meat and meat products are limited or avoided.
Study: NCT06697769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: breastfeeding simulation with virtual reality glasses
Study: NCT06697860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Shockwave Therapy
Description: In Group A, Radial Shockwave Therapy (RST) was given to the plantar fascia for 5 minutes, with each session consisting of 5-10 shock wave pulses of varied intensity. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each stretch. This therapy procedure was followed out in weekly sessions for 8 weeks, each lasting 40 minutes in total.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston Instrument
Description: Group B employed Graston Instrument-Assisted Soft Tissue Mobilization (IASTM) for 5-10 minutes to target and break down plantar fascia adhesions. The therapist used a specialized device to apply controlled, precise pressure to the fascia. Following that, stretching exercises for the plantar fascia and calf muscles were done for 30 minutes, with three sets of 30-second holds for each. The entire therapy procedure was carried out in weekly sessions for 8 weeks, each lasting 40 minutes in total..
Study: NCT06696703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human urinary kininogenase(HUK)
Description: Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group (Normal sodium chloride injection plus routine clinical treatment): Normal sodium chloride administered within 48 hours of AIS onset, by intravenous infusion for not less than 50 minutes, once a day.